| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.31 | 4e-22 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-11 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-11 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-10 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.3 | 4e-10 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-08 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-07 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |